Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.5.76NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.76NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.5.39NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.39NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.39NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.5.43NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.43NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.43NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
GY.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GY.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GY.5NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
FL.4.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.4.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.4.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.5.107NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.107NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.107NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.5.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.7NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.7NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JN.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.11NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.11NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
LC.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LC.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
LC.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
LF.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LF.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
LF.4NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.5.2.39NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.39NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.39NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
HZ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HZ.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
HZ.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.172NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.172NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.172NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.110NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.110NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.110NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.320NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.320NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.320NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
A.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
A.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
A.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.5.91NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.91NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.91NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used